Dr. Rider is a board-certified, fellowship-trained neuromuscular neurologist with the Neuromuscular Program at the Stanford Neuroscience Health Center. He is also a clinical assistant professor in the Department of Neurology & Neurological Sciences at Stanford University School of Medicine.

Dr. Rider specializes in treating neuromuscular disease, including motor neuron disease, disorders of the neuromuscular junction, peripheral and focal neuropathies, as well as other acquired or genetic conditions that cause muscular deterioration, muscle weakness, and nerve damage. He practices both Comprehensive Neurology and Neuromuscular Medicine in Palo Alto and Emeryville.

Dr. Rider earned his medical degree at the University of California, San Francisco and completed residency at Stanford. He also completed fellowship training in Neuromuscular Medicine at UCSF. He has a passion for teaching neurology to students and patients. He was awarded the Fishers and Dunn teaching award for medical student teaching as a resident.
Dr. Rider is a member of the American Academy of Neurology and American Association of Neuromuscular & Electrodiagnostic Medicine.

Clinical Focus

  • Neurology

Academic Appointments

Professional Education

  • Residency: Stanford University Dept of Neurology (2020) CA
  • Board Certification: American Board of Psychiatry and Neurology, Neuromuscular Medicine (2022)
  • Fellowship: UCSF Neurology Fellowship Programs (2021) CA
  • Board Certification: American Board of Psychiatry and Neurology, Neurology (2020)
  • Internship: California Pacific Medical Center Internal Medicine Residency (2017) CA
  • Medical Education: University of California at San Francisco School of Medicine (2016) CA

All Publications

  • DRAXIN regulates interhemispheric fissure remodelling to influence the extent of corpus callosum formation. eLife Morcom, L., Edwards, T. J., Rider, E., Jones-Davis, D., Lim, J. W., Chen, K. S., Dean, R. J., Bunt, J., Ye, Y., Gobius, I., Suárez, R., Mandelstam, S., Sherr, E. H., Richards, L. J. 2021; 10


    Corpus callosum dysgenesis (CCD) is a congenital disorder that incorporates either partial or complete absence of the largest cerebral commissure. Remodelling of the interhemispheric fissure (IHF) provides a substrate for callosal axons to cross between hemispheres, and its failure is the main cause of complete CCD. However, it is unclear whether defects in this process could give rise to the heterogeneity of expressivity and phenotypes seen in human cases of CCD. We identify incomplete IHF remodelling as the key structural correlate for the range of callosal abnormalities in inbred and outcrossed BTBR mouse strains, as well as in humans with partial CCD. We identify an eight base-pair deletion in Draxin and misregulated astroglial and leptomeningeal proliferation as genetic and cellular factors for variable IHF remodelling and CCD in BTBR strains. These findings support a model where genetic events determine corpus callosum structure by influencing leptomeningeal-astroglial interactions at the IHF.

    View details for DOI 10.7554/eLife.61618

    View details for PubMedID 33945466

    View details for PubMedCentralID PMC8137145

  • Young Man With Paraparesis. Annals of emergency medicine Rider, E. n., Gold, C. A. 2018; 72 (3): e19–e20

    View details for PubMedID 30144875

  • Mapk/Erk activation in an animal model of social deficits shows a possible link to autism. Molecular autism Faridar, A., Jones-Davis, D., Rider, E., Li, J., Gobius, I., Morcom, L., Richards, L. J., Sen, S., Sherr, E. H. 2014; 5: 57


    There is converging preclinical and clinical evidence to suggest that the extracellular signal-regulated kinase (ERK) signaling pathway may be dysregulated in autism spectrum disorders.We evaluated Mapk/Erk1/2, cellular proliferation and apoptosis in BTBR mice, as a preclinical model of Autism. We had previously generated 410 F2 mice from the cross of BTBR with B6. At that time, six different social behaviors in all F2 mice were evaluated and scored. In this study, eight mice at each extreme of the social behavioral spectrum were selected and the expression and activity levels of Mapk/Erk in the prefrontal cortex and cerebellum of these mice were compared. Finally, we compared the Mapk/Erk signaling pathway in brain and lymphocytes of the same mice, testing for correlation in the degree of kinase activation across these separate tissues.Levels of phosphorylated Erk (p-Erk) were significantly increased in the brains of BTBR versus control mice. We also observed a significant association between juvenile social behavior and phosphorylated mitogen-activated protein kinase kinase (p-Mek) and p-Erk levels in the prefrontal cortex but not in the cerebellum. In contrast, we did not find a significant association between social behavior and total protein levels of either Mek or Erk. We also tested whether steady-state levels of Erk activation in the cerebral cortex in individual animals correlated with levels of Erk activation in lymphocytes, finding a significant relationship for this signaling pathway.These observations suggest that dysregulation of the ERK signaling pathway may be an important mediator of social behavior, and that measuring activation of this pathway in peripheral lymphocytes may serve as a surrogate marker for central nervous system (CNS) ERK activity, and possibly autistic behavior.

    View details for DOI 10.1186/2040-2392-5-57

    View details for PubMedID 25874073

    View details for PubMedCentralID PMC4396809

  • Both rare and de novo copy number variants are prevalent in agenesis of the corpus callosum but not in cerebellar hypoplasia or polymicrogyria. PLoS genetics Sajan, S. A., Fernandez, L., Nieh, S. E., Rider, E., Bukshpun, P., Wakahiro, M., Christian, S. L., Rivière, J. B., Sullivan, C. T., Sudi, J., Herriges, M. J., Paciorkowski, A. R., Barkovich, A. J., Glessner, J. T., Millen, K. J., Hakonarson, H., Dobyns, W. B., Sherr, E. H. 2013; 9 (10): e1003823


    Agenesis of the corpus callosum (ACC), cerebellar hypoplasia (CBLH), and polymicrogyria (PMG) are severe congenital brain malformations with largely undiscovered causes. We conducted a large-scale chromosomal copy number variation (CNV) discovery effort in 255 ACC, 220 CBLH, and 147 PMG patients, and 2,349 controls. Compared to controls, significantly more ACC, but unexpectedly not CBLH or PMG patients, had rare genic CNVs over one megabase (p = 1.48×10⁻³; odds ratio [OR] = 3.19; 95% confidence interval [CI] = 1.89-5.39). Rare genic CNVs were those that impacted at least one gene in less than 1% of the combined population of patients and controls. Compared to controls, significantly more ACC but not CBLH or PMG patients had rare CNVs impacting over 20 genes (p = 0.01; OR = 2.95; 95% CI = 1.69-5.18). Independent qPCR confirmation showed that 9.4% of ACC patients had de novo CNVs. These, in comparison to inherited CNVs, preferentially overlapped de novo CNVs previously observed in patients with autism spectrum disorders (p = 3.06×10⁻⁴; OR = 7.55; 95% CI = 2.40-23.72). Interestingly, numerous reports have shown a reduced corpus callosum area in autistic patients, and diminished social and executive function in many ACC patients. We also confirmed and refined previously known CNVs, including significantly narrowing the 8p23.1-p11.1 duplication present in 2% of our current ACC cohort. We found six novel CNVs, each in a single patient, that are likely deleterious: deletions of 1p31.3-p31.1, 1q31.2-q31.3, 5q23.1, and 15q11.2-q13.1; and duplications of 2q11.2-q13 and 11p14.3-p14.2. One ACC patient with microcephaly had a paternally inherited deletion of 16p13.11 that included NDE1. Exome sequencing identified a recessive maternally inherited nonsense mutation in the non-deleted allele of NDE1, revealing the complexity of ACC genetics. This is the first systematic study of CNVs in congenital brain malformations, and shows a much higher prevalence of large gene-rich CNVs in ACC than in CBLH and PMG.

    View details for DOI 10.1371/journal.pgen.1003823

    View details for PubMedID 24098143

    View details for PubMedCentralID PMC3789824

  • Quantitative trait loci for interhemispheric commissure development and social behaviors in the BTBR T⁺ tf/J mouse model of autism. PloS one Jones-Davis, D. M., Yang, M., Rider, E., Osbun, N. C., da Gente, G. J., Li, J., Katz, A. M., Weber, M. D., Sen, S., Crawley, J., Sherr, E. H. 2013; 8 (4): e61829


    Autism and Agenesis of the Corpus Callosum (AgCC) are interrelated behavioral and anatomic phenotypes whose genetic etiologies are incompletely understood. We used the BTBR T⁺ tf/J (BTBR) strain, exhibiting fully penetrant AgCC, a diminished hippocampal commissure, and abnormal behaviors that may have face validity to autism, to study the genetic basis of these disorders.We generated 410 progeny from an F2 intercross between the BTBR and C57BL/6J strains. The progeny were phenotyped for social behaviors (as juveniles and adults) and commisural morphology, and genotyped using 458 markers. Quantitative trait loci (QTL) were identified using genome scans; significant loci were fine-mapped, and the BTBR genome was sequenced and analyzed to identify candidate genes.Six QTL meeting genome-wide significance for three autism-relevant behaviors in BTBR were identified on chromosomes 1, 3, 9, 10, 12, and X. Four novel QTL for commissural morphology on chromosomes 4, 6, and 12 were also identified. We identified a highly significant QTL (LOD score = 20.2) for callosal morphology on the distal end of chromosome 4.We identified several QTL and candidate genes for both autism-relevant traits and commissural morphology in the BTBR mouse. Twenty-nine candidate genes were associated with synaptic activity, axon guidance, and neural development. This is consistent with a role for these processes in modulating white matter tract development and aspects of autism-relevant behaviors in the BTBR mouse. Our findings reveal candidate genes in a mouse model that will inform future human and preclinical studies of autism and AgCC.

    View details for DOI 10.1371/journal.pone.0061829

    View details for PubMedID 23613947

    View details for PubMedCentralID PMC3626795

  • Genetic and functional analyses identify DISC1 as a novel callosal agenesis candidate gene. American journal of medical genetics. Part A Osbun, N., Li, J., O'Driscoll, M. C., Strominger, Z., Wakahiro, M., Rider, E., Bukshpun, P., Boland, E., Spurrell, C. H., Schackwitz, W., Pennacchio, L. A., Dobyns, W. B., Black, G. C., Sherr, E. H. 2011; 155A (8): 1865-76


    Agenesis of the corpus callosum (AgCC) is a congenital brain malformation that occurs in approximately 1:1,000-1:6,000 births. Several syndromes associated with AgCC have been traced to single gene mutations; however, the majority of AgCC causes remain unidentified. We investigated a mother and two children who all shared complete AgCC and a chromosomal deletion at 1q42. We fine mapped this deletion and show that it includes Disrupted-in-Schizophrenia 1 (DISC1), a gene implicated in schizophrenia and other psychiatric disorders. Furthermore, we report a de novo chromosomal deletion at 1q42.13 to q44, which includes DISC1, in another individual with AgCC. We resequenced DISC1 in a cohort of 144 well-characterized AgCC individuals and identified 20 sequence changes, of which 4 are rare potentially pathogenic variants. Two of these variants were undetected in 768 control chromosomes. One of these is a splice site mutation at the 5' boundary of exon 11 that dramatically reduces full-length mRNA expression of DISC1, but not of shorter forms. We investigated the developmental expression of mouse DISC1 and find that it is highly expressed in the embryonic corpus callosum at a critical time for callosal formation. Taken together our results suggest a significant role for DISC1 in corpus callosum development.

    View details for DOI 10.1002/ajmg.a.34081

    View details for PubMedID 21739582

    View details for PubMedCentralID PMC5544936